Original article by
abc.net.au – Page: Online : 26-Mar-25

Swiss pharmaceutical company Novartis is taking cancer care provider GenesisCare to the Federal Court over GenesisCare’s use of a treatment for metastatic prostate cancer called Lutetium PSMA I&T, which has been approved by the Therapeutic Goods Adminstration. Novartis argues that Lutetium PSMA I&T infringes on the company’s patent for a similar product known as Pluvicto; if its action succeeds, it will reduce the treatment options for men suffering from metastatic prostate cancer. The lawsuit was discussed on ABC Radio National Breakfast by Professor Sze Ting Lee, who chair the Australasian Association of Nuclear Medicine Specialists Theranostics Committee.

CORPORATES
NOVARTIS AG, GENESIS CARE PTY LTD, AUSTRALIA. THERAPEUTIC GOODS ADMINISTRATION